MersV1, PubMed, Curation, bibRecord, 000125

The SARS-CoV-2 Vaccine Pipeline: an Overview.

Identifieur interne : 000125 ( PubMed/Curation ); précédent : 000124; suivant : 000126

The SARS-CoV-2 Vaccine Pipeline: an Overview.

Auteurs : Wen-Hsiang Chen [États-Unis] ; Ulrich Strych [États-Unis] ; Peter J. Hotez [États-Unis] ; Maria Elena Bottazzi [États-Unis]

Source :

Current tropical medicine reports [ 2196-3045 ] ; 2020.

RBID : pubmed:32219057

Abstract

The goal of this review is to provide a timely overview on efforts to develop a vaccine for the 2019 novel coronavirus SARS-CoV-2, the causative agent of coronavirus disease (COVID-19).

DOI: 10.1007/s40475-020-00201-6
PubMed: 32219057

Links toward previous steps (curation, corpus...)

to stream PubMed, to step Corpus: Pour aller vers cette notice dans l'étape Curation :000125

Links to Exploration step

pubmed:32219057

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">The SARS-CoV-2 Vaccine Pipeline: an Overview.</title>
<author><name sortKey="Chen, Wen Hsiang" sort="Chen, Wen Hsiang" uniqKey="Chen W" first="Wen-Hsiang" last="Chen">Wen-Hsiang Chen</name>
<affiliation wicri:level="2"><nlm:affiliation>Texas Children's Hospital Center for Vaccine Development, Departments of Pediatrics and Molecular Virology & Microbiology, National School of Tropical Medicine, Baylor College of Medicine, Houston, TX USA.</nlm:affiliation>
<country>États-Unis</country>
<placeName><region type="state">Texas</region>
</placeName>
<wicri:cityArea>Texas Children's Hospital Center for Vaccine Development, Departments of Pediatrics and Molecular Virology & Microbiology, National School of Tropical Medicine, Baylor College of Medicine, Houston</wicri:cityArea>
</affiliation>
</author>
<author><name sortKey="Strych, Ulrich" sort="Strych, Ulrich" uniqKey="Strych U" first="Ulrich" last="Strych">Ulrich Strych</name>
<affiliation wicri:level="2"><nlm:affiliation>Texas Children's Hospital Center for Vaccine Development, Departments of Pediatrics and Molecular Virology & Microbiology, National School of Tropical Medicine, Baylor College of Medicine, Houston, TX USA.</nlm:affiliation>
<country>États-Unis</country>
<placeName><region type="state">Texas</region>
</placeName>
<wicri:cityArea>Texas Children's Hospital Center for Vaccine Development, Departments of Pediatrics and Molecular Virology & Microbiology, National School of Tropical Medicine, Baylor College of Medicine, Houston</wicri:cityArea>
</affiliation>
</author>
<author><name sortKey="Hotez, Peter J" sort="Hotez, Peter J" uniqKey="Hotez P" first="Peter J" last="Hotez">Peter J. Hotez</name>
<affiliation wicri:level="2"><nlm:affiliation>Texas Children's Hospital Center for Vaccine Development, Departments of Pediatrics and Molecular Virology & Microbiology, National School of Tropical Medicine, Baylor College of Medicine, Houston, TX USA.</nlm:affiliation>
<country>États-Unis</country>
<placeName><region type="state">Texas</region>
</placeName>
<wicri:cityArea>Texas Children's Hospital Center for Vaccine Development, Departments of Pediatrics and Molecular Virology & Microbiology, National School of Tropical Medicine, Baylor College of Medicine, Houston</wicri:cityArea>
</affiliation>
</author>
<author><name sortKey="Bottazzi, Maria Elena" sort="Bottazzi, Maria Elena" uniqKey="Bottazzi M" first="Maria Elena" last="Bottazzi">Maria Elena Bottazzi</name>
<affiliation wicri:level="2"><nlm:affiliation>Texas Children's Hospital Center for Vaccine Development, Departments of Pediatrics and Molecular Virology & Microbiology, National School of Tropical Medicine, Baylor College of Medicine, Houston, TX USA.</nlm:affiliation>
<country>États-Unis</country>
<placeName><region type="state">Texas</region>
</placeName>
<wicri:cityArea>Texas Children's Hospital Center for Vaccine Development, Departments of Pediatrics and Molecular Virology & Microbiology, National School of Tropical Medicine, Baylor College of Medicine, Houston</wicri:cityArea>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="2020">2020</date>
<idno type="RBID">pubmed:32219057</idno>
<idno type="pmid">32219057</idno>
<idno type="doi">10.1007/s40475-020-00201-6</idno>
<idno type="wicri:Area/PubMed/Corpus">000125</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000125</idno>
<idno type="wicri:Area/PubMed/Curation">000125</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">000125</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">The SARS-CoV-2 Vaccine Pipeline: an Overview.</title>
<author><name sortKey="Chen, Wen Hsiang" sort="Chen, Wen Hsiang" uniqKey="Chen W" first="Wen-Hsiang" last="Chen">Wen-Hsiang Chen</name>
<affiliation wicri:level="2"><nlm:affiliation>Texas Children's Hospital Center for Vaccine Development, Departments of Pediatrics and Molecular Virology & Microbiology, National School of Tropical Medicine, Baylor College of Medicine, Houston, TX USA.</nlm:affiliation>
<country>États-Unis</country>
<placeName><region type="state">Texas</region>
</placeName>
<wicri:cityArea>Texas Children's Hospital Center for Vaccine Development, Departments of Pediatrics and Molecular Virology & Microbiology, National School of Tropical Medicine, Baylor College of Medicine, Houston</wicri:cityArea>
</affiliation>
</author>
<author><name sortKey="Strych, Ulrich" sort="Strych, Ulrich" uniqKey="Strych U" first="Ulrich" last="Strych">Ulrich Strych</name>
<affiliation wicri:level="2"><nlm:affiliation>Texas Children's Hospital Center for Vaccine Development, Departments of Pediatrics and Molecular Virology & Microbiology, National School of Tropical Medicine, Baylor College of Medicine, Houston, TX USA.</nlm:affiliation>
<country>États-Unis</country>
<placeName><region type="state">Texas</region>
</placeName>
<wicri:cityArea>Texas Children's Hospital Center for Vaccine Development, Departments of Pediatrics and Molecular Virology & Microbiology, National School of Tropical Medicine, Baylor College of Medicine, Houston</wicri:cityArea>
</affiliation>
</author>
<author><name sortKey="Hotez, Peter J" sort="Hotez, Peter J" uniqKey="Hotez P" first="Peter J" last="Hotez">Peter J. Hotez</name>
<affiliation wicri:level="2"><nlm:affiliation>Texas Children's Hospital Center for Vaccine Development, Departments of Pediatrics and Molecular Virology & Microbiology, National School of Tropical Medicine, Baylor College of Medicine, Houston, TX USA.</nlm:affiliation>
<country>États-Unis</country>
<placeName><region type="state">Texas</region>
</placeName>
<wicri:cityArea>Texas Children's Hospital Center for Vaccine Development, Departments of Pediatrics and Molecular Virology & Microbiology, National School of Tropical Medicine, Baylor College of Medicine, Houston</wicri:cityArea>
</affiliation>
</author>
<author><name sortKey="Bottazzi, Maria Elena" sort="Bottazzi, Maria Elena" uniqKey="Bottazzi M" first="Maria Elena" last="Bottazzi">Maria Elena Bottazzi</name>
<affiliation wicri:level="2"><nlm:affiliation>Texas Children's Hospital Center for Vaccine Development, Departments of Pediatrics and Molecular Virology & Microbiology, National School of Tropical Medicine, Baylor College of Medicine, Houston, TX USA.</nlm:affiliation>
<country>États-Unis</country>
<placeName><region type="state">Texas</region>
</placeName>
<wicri:cityArea>Texas Children's Hospital Center for Vaccine Development, Departments of Pediatrics and Molecular Virology & Microbiology, National School of Tropical Medicine, Baylor College of Medicine, Houston</wicri:cityArea>
</affiliation>
</author>
</analytic>
<series><title level="j">Current tropical medicine reports</title>
<idno type="ISSN">2196-3045</idno>
<imprint><date when="2020" type="published">2020</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass></textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">The goal of this review is to provide a timely overview on efforts to develop a vaccine for the 2019 novel coronavirus SARS-CoV-2, the causative agent of coronavirus disease (COVID-19).</div>
</front>
</TEI>
<pubmed><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">32219057</PMID>
<DateRevised><Year>2020</Year>
<Month>03</Month>
<Day>31</Day>
</DateRevised>
<Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Print">2196-3045</ISSN>
<JournalIssue CitedMedium="Print"><PubDate><Year>2020</Year>
<Month>Mar</Month>
<Day>03</Day>
</PubDate>
</JournalIssue>
<Title>Current tropical medicine reports</Title>
<ISOAbbreviation>Curr Trop Med Rep</ISOAbbreviation>
</Journal>
<ArticleTitle>The SARS-CoV-2 Vaccine Pipeline: an Overview.</ArticleTitle>
<Pagination><MedlinePgn>1-4</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1007/s40475-020-00201-6</ELocationID>
<Abstract><AbstractText Label="Purpose of Review" NlmCategory="UNASSIGNED">The goal of this review is to provide a timely overview on efforts to develop a vaccine for the 2019 novel coronavirus SARS-CoV-2, the causative agent of coronavirus disease (COVID-19).</AbstractText>
<AbstractText Label="Recent Findings" NlmCategory="UNASSIGNED">Previous research efforts to develop a severe acute respiratory syndrome coronavirus (SARS-CoV) vaccine in the years following the 2003 pandemic have opened the door for investigators to design vaccine concepts and approaches for the COVID-19 epidemic in China. Both SARS-CoV and SARS-CoV-2 exhibit a high degree of genetic similarity and bind to the same host cell ACE2 receptor. Based on previous experience with SARS-CoV vaccines, it is expected that all COVID-19 vaccines will require careful safety evaluations for immunopotentiation that could lead to increased infectivity or eosinophilic infiltration. Besides this, a COVID-19 vaccine target product profile must address vaccinating at-risk human populations including frontline healthcare workers, individuals over the age of 60, and those with underlying and debilitating chronic conditions. Among the vaccine technologies under evaluation are whole virus vaccines, recombinant protein subunit vaccines, and nucleic acid vaccines.</AbstractText>
<AbstractText Label="Summary" NlmCategory="UNASSIGNED">Each current vaccine strategy has distinct advantages and disadvantages. Therefore, it is paramount that multiple strategies be advanced quickly and then evaluated for safety and efficacy. Ultimately, the safety studies to minimize undesired immunopotentiation will become the most significant bottleneck in terms of time.</AbstractText>
<CopyrightInformation>© Springer Nature Switzerland AG 2020.</CopyrightInformation>
</Abstract>
<AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Chen</LastName>
<ForeName>Wen-Hsiang</ForeName>
<Initials>WH</Initials>
<Identifier Source="ORCID">https://orcid.org/0000-0002-0542-1598</Identifier>
<AffiliationInfo><Affiliation>Texas Children's Hospital Center for Vaccine Development, Departments of Pediatrics and Molecular Virology & Microbiology, National School of Tropical Medicine, Baylor College of Medicine, Houston, TX USA.</Affiliation>
<Identifier Source="GRID">grid.39382.33</Identifier>
<Identifier Source="ISNI">0000 0001 2160 926X</Identifier>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Strych</LastName>
<ForeName>Ulrich</ForeName>
<Initials>U</Initials>
<Identifier Source="ORCID">https://orcid.org/0000-0001-9455-7683</Identifier>
<AffiliationInfo><Affiliation>Texas Children's Hospital Center for Vaccine Development, Departments of Pediatrics and Molecular Virology & Microbiology, National School of Tropical Medicine, Baylor College of Medicine, Houston, TX USA.</Affiliation>
<Identifier Source="GRID">grid.39382.33</Identifier>
<Identifier Source="ISNI">0000 0001 2160 926X</Identifier>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Hotez</LastName>
<ForeName>Peter J</ForeName>
<Initials>PJ</Initials>
<Identifier Source="ORCID">https://orcid.org/0000-0001-8770-1042</Identifier>
<AffiliationInfo><Affiliation>Texas Children's Hospital Center for Vaccine Development, Departments of Pediatrics and Molecular Virology & Microbiology, National School of Tropical Medicine, Baylor College of Medicine, Houston, TX USA.</Affiliation>
<Identifier Source="GRID">grid.39382.33</Identifier>
<Identifier Source="ISNI">0000 0001 2160 926X</Identifier>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Bottazzi</LastName>
<ForeName>Maria Elena</ForeName>
<Initials>ME</Initials>
<Identifier Source="ORCID">https://orcid.org/0000-0002-8429-0476</Identifier>
<AffiliationInfo><Affiliation>Texas Children's Hospital Center for Vaccine Development, Departments of Pediatrics and Molecular Virology & Microbiology, National School of Tropical Medicine, Baylor College of Medicine, Houston, TX USA.</Affiliation>
<Identifier Source="GRID">grid.39382.33</Identifier>
<Identifier Source="ISNI">0000 0001 2160 926X</Identifier>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D016454">Review</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic"><Year>2020</Year>
<Month>03</Month>
<Day>03</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo><Country>Switzerland</Country>
<MedlineTA>Curr Trop Med Rep</MedlineTA>
<NlmUniqueID>101625249</NlmUniqueID>
</MedlineJournalInfo>
<KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID-19</Keyword>
<Keyword MajorTopicYN="N">Coronavirus</Keyword>
<Keyword MajorTopicYN="N">RBD</Keyword>
<Keyword MajorTopicYN="N">Receptor binding domain</Keyword>
<Keyword MajorTopicYN="N">Wuhan virus</Keyword>
</KeywordList>
<CoiStatement>Conflict of InterestThe authors have developed subunit vaccines against SARS and MERS coronavirus infections. They are involved in the process of developing a vaccine against SARS-CoV-2.</CoiStatement>
</MedlineCitation>
<PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2020</Year>
<Month>3</Month>
<Day>29</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="pubmed"><Year>2020</Year>
<Month>3</Month>
<Day>29</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="medline"><Year>2020</Year>
<Month>3</Month>
<Day>29</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
</History>
<PublicationStatus>aheadofprint</PublicationStatus>
<ArticleIdList><ArticleId IdType="pubmed">32219057</ArticleId>
<ArticleId IdType="doi">10.1007/s40475-020-00201-6</ArticleId>
<ArticleId IdType="pii">201</ArticleId>
<ArticleId IdType="pmc">PMC7094941</ArticleId>
</ArticleIdList>
<pmc-dir>pmcsd</pmc-dir>
        <ReferenceList><Reference><Citation>Expert Rev Vaccines. 2012 Dec;11(12):1405-13</Citation>
<ArticleIdList><ArticleId IdType="pubmed">23252385</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Vaccine. 2014 May 30;32(26):3169-3174</Citation>
<ArticleIdList><ArticleId IdType="pubmed">24736006</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>J Pharm Sci. 2017 Aug;106(8):1961-1970</Citation>
<ArticleIdList><ArticleId IdType="pubmed">28456726</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
</PubmedData>
</pubmed>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Sante/explor/MersV1/Data/PubMed/Curation

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000125 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/PubMed/Curation/biblio.hfd -nk 000125 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Sante
   |area=    MersV1
   |flux=    PubMed
   |étape=   Curation
   |type=    RBID
   |clé=     pubmed:32219057
   |texte=   The SARS-CoV-2 Vaccine Pipeline: an Overview.
}}

Pour générer des pages wiki

HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Curation/RBID.i   -Sk "pubmed:32219057" \
       | HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Curation/biblio.hfd   \
       | NlmPubMed2Wicri -a MersV1

This area was generated with Dilib version V0.6.33.
Data generation: Mon Apr 20 23:26:43 2020. Site generation: Sat Mar 27 09:06:09 2021

	Serveur d'exploration MERS
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

Serveur d'exploration MERS

The SARS-CoV-2 Vaccine Pipeline: an Overview.

The SARS-CoV-2 Vaccine Pipeline: an Overview.

Source :

Abstract

Links toward previous steps (curation, corpus...)

Links to Exploration step

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri

Pour générer des pages wiki